These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34533506)

  • 1. Pegaspargase: Two Pediatric Case Studies of Delayed Urticaria Preceding Anaphylactic Reactions Postadministration.
    Busack KR
    Clin J Oncol Nurs; 2021 Oct; 25(5):511-513. PubMed ID: 34533506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia.
    Kaminski KS; Beach CL; Peden DB; Le U; Roehrs PA
    J Oncol Pharm Pract; 2016 Apr; 22(2):354-6. PubMed ID: 25567519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated
    Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
    Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and Efficacy of a 1-Bag Pegaspargase Densensitization Protocol in Pediatric Oncology Patients.
    Cramer J; Graff J; Serebin D
    J Pediatr Hematol Oncol; 2022 Apr; 44(3):e623-e627. PubMed ID: 34133383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
    Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
    Burke MJ; Devidas M; Maloney K; Angiolillo A; Schore R; Dunsmore K; Larsen E; Mattano LA; Salzer W; Winter SS; Carroll W; Winick NJ; Loh ML; Raetz E; Hunger SP; Bleyer A
    Leuk Lymphoma; 2018 Jul; 59(7):1624-1633. PubMed ID: 29115886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
    MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock).
    Limsuwan T; Demoly P
    Med Clin North Am; 2010 Jul; 94(4):691-710, x. PubMed ID: 20609858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
    Lau KM; Saunders IM; Goodman A
    J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Beaupin LK; Bostrom B; Barth MJ; Franklin I; Jaeger R; Kamath P; Schreiber B; Bleyer A
    Leuk Lymphoma; 2017 Apr; 58(4):766-772. PubMed ID: 27643446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergic reactions associated with pegaspargase in adults.
    Chang A; Kim M; Seyer M; Patel S
    Leuk Lymphoma; 2016 Jul; 57(7):1665-8. PubMed ID: 26461960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
    Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
    J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
    Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
    Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycols.
    Co-Minh HB; Demoly P; Guillot B; Raison-Peyron N
    Allergy; 2007 Jan; 62(1):92-3. PubMed ID: 17156356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
    Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
    Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.